TY - JOUR
T1 - Chemotherapy-induced hepatotoxicity
AU - Thatishetty, Ameet V.
AU - Agresti, Nicholas
AU - O'Brien, Christopher B.
PY - 2013/11/1
Y1 - 2013/11/1
N2 - Most hepatotoxicity secondary to chemotherapy is idiosyncratic and, therefore, neither dose dependent nor predictable. Some chemotherapy is cleared by the liver and requires dose adjustment in the face of significant liver dysfunction. In addition, preexisting abnormal liver function has been shown to increase the risk of hepatotoxicity. In addition to typical hepatocellular injury, other presentations, including cholestasis and hepatic sinusoidal obstruction syndrome, also commonly occur. The outcomes can range from asymptomatic liver function test abnormalities, which resolve spontaneously, to cirrhosis, which occurs despite discontinuation of the chemotherapeutic agent.
AB - Most hepatotoxicity secondary to chemotherapy is idiosyncratic and, therefore, neither dose dependent nor predictable. Some chemotherapy is cleared by the liver and requires dose adjustment in the face of significant liver dysfunction. In addition, preexisting abnormal liver function has been shown to increase the risk of hepatotoxicity. In addition to typical hepatocellular injury, other presentations, including cholestasis and hepatic sinusoidal obstruction syndrome, also commonly occur. The outcomes can range from asymptomatic liver function test abnormalities, which resolve spontaneously, to cirrhosis, which occurs despite discontinuation of the chemotherapeutic agent.
KW - Cancer
KW - Chemotherapy
KW - Drugs
KW - Hepatotoxicity
KW - Liver
UR - http://www.scopus.com/inward/record.url?scp=84884981466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884981466&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2013.07.010
DO - 10.1016/j.cld.2013.07.010
M3 - Review article
C2 - 24099024
AN - SCOPUS:84884981466
VL - 17
SP - 671
EP - 686
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
SN - 1089-3261
IS - 4
ER -